Mapping knowledge domains analysis of gastrointestinal stromal tumor research_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

SU Xiangnan ,  WU Xiaoting

Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

WU Xiaoting, Email: wxt1@medmail.com.cn

Keywords：

gastrointestinal stromal tumor; CiteSpace; VOSviewer; visualization analysis; knowledge domain analysis

DOI：

10.7507/1007-9424.202001068

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the current status and hotspots in researches of gastrointestinal stromal tumor.Methods The literatures related to gastrointestinal stromal tumor and published from 2000 to 2019 were extracted from Web of Science Core Collection. Visualization analysis was conducted by utilizing CiteSpace and VOSviewer software based on bibliometrics methods.Results A total of 3 226 articles and reviews were retrieved. The number of publications increased from 2000 to 2019, from the initial 34 publications gradually increased to 241 in 2019, and the maximum number of publications was 265 in 2015. The most productive five countries in terms of publication number were: 907 in the United States, 540 in China, 522 in Japan, 219 in Germany, and 214 in Italy. Co-occurrence networks of keywords were divided into three clusters: targeted therapy, clinical management, and pathogenesis research. Co-citation analysis of literatures contained 9 clusters, and cluster #0 prognosis was the latest cluster, indicating the research frontier and tendency.Conclusions The United States and its domestic institutes are the pioneers. Targeted therapy, clinical management, and pathogenesis researches are the main research filed. Prognosis research may be the new research tendency, and clinical and basic researches are still hotspots in medical research.

Citation： SU Xiangnan, WU Xiaoting. Mapping knowledge domains analysis of gastrointestinal stromal tumor research. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(10): 1241-1244. doi: 10.7507/1007-9424.202001068 Copy

1.	Akahoshi K, Oya M, Koga T, <italic>et al</italic>. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol, 2018, 24(26): 2806-2817.
2.	Heinrich MC, Corless CL, Duensing A, <italic>et al</italic>. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607): 708-710.
3.	Hirota S, Isozaki K, Moriyama Y, <italic>et al</italic>. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580.
4.	Patel N, Benipal B. Incidence of gastrointestinal stromal tumors in the United States from 2001-2015: a United States cancer statistics analysis of 50 states. Cureus, 2019, 11(2): e4120.
5.	梁小波, 于红宾, 王立平. 胃肠道间质瘤的临床流行病学调查. 肿瘤研究与临床, 2006, 18(8): 505-507.
6.	陈悦, 陈超美, 刘则渊, 等. CiteSpace 知识图谱的方法论功能. 科学学研究, 2015, 33(2): 242-253.
7.	van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 2010, 84(2): 523-538.
8.	李佼, 周银斌, 周小林, 等. 基于 2013 年至 2017 年 Cite Space 的胃癌手术文献的可视化研究. 局解手术学杂志, 2019, 28(3): 177-182.
9.	黄子星, 李谋, 于浩鹏, 等. 基于 CiteSpace 的胰腺神经内分泌肿瘤影像研究的科学知识图谱分析. 中国普外基础与临床杂志, 2019, 26(1): 96-101.
10.	Wu CE, Tzen CY, Wang SY, <italic>et al</italic>. Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view. Cancers (Basel), 2019, 11(5): 679.
11.	Demetri GD, von Mehren M, Blanke CD, <italic>et al</italic>. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
12.	Dematteo RP, Ballman KV, Antonescu CR, <italic>et al</italic>. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 373(9669): 1097-1104.
13.	Demetri GD, van Oosterom AT, Garrett CR, <italic>et al</italic>. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544): 1329-1338.
14.	Demetri GD, Reichardt P, Kang YK, <italic>et al</italic>. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 295-302.
15.	Guo Y, Jing X, Zhang J, <italic>et al</italic>. Endoscopic removal of gastrointestinal stromal tumors in the stomach: a single-center experience. Gastroenterol Res Pract, 2019, 2019: 3087298.
16.	De Vogelaere K, Hoorens A, Haentjens P, <italic>et al</italic>. Laparoscopic <italic>versus</italic> open resection of gastrointestinal stromal tumors of the stomach. Surg Endosc, 2013, 27(5): 1546-1554.
17.	Matsuhashi N, Osada S, Yamaguchi K, <italic>et al</italic>. Long-term outcomes of treatment of gastric gastrointestinal stromal tumor by laparoscopic surgery: review of the literature and our experience. Hepatogastroenterology, 2013, 60(128): 2011-2015.
18.	Mei L, Du W, Idowu M, <italic>et al</italic>. Advances and challenges on management of gastrointestinal stromal tumors. Front Oncol, 2018, 8: 135.
19.	Rutkowski P, Jagielska B, Andrzejuk J, <italic>et al</italic>. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). Contemp Oncol (Pozn), 2017, 21(4): 285-289.
20.	夏训明. 美国 FDA 批准 Ayvakit (avapritinib)用于治疗 PDGFRA 基因 18 外显子突变型胃肠道间质瘤. 广东药科大学学报, 2020, 36(1): 27.
21.	Mazzocca A, Napolitano A, Silletta M, <italic>et al</italic>. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol, 2019, 11: 1758835919841946.
22.	Tan Y, Trent JC, Wilky BA, <italic>et al</italic>. Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Ther, 2017, 24(3): 130-133.
23.	Chen LL, Chen X, Choi H, <italic>et al</italic>. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother, 2012, 61(7): 1113-1124.
24.	Balachandran VP, Cavnar MJ, Zeng S, <italic>et al</italic>. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med, 2011, 17(9): 1094-1100.
25.	Edris B, Willingham S, Weiskopf K, <italic>et al</italic>. Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncoimmunology, 2013, 2(6): e24452.

1. Akahoshi K, Oya M, Koga T, <italic>et al</italic>. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol, 2018, 24(26): 2806-2817.
2. Heinrich MC, Corless CL, Duensing A, <italic>et al</italic>. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607): 708-710.
3. Hirota S, Isozaki K, Moriyama Y, <italic>et al</italic>. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580.
4. Patel N, Benipal B. Incidence of gastrointestinal stromal tumors in the United States from 2001-2015: a United States cancer statistics analysis of 50 states. Cureus, 2019, 11(2): e4120.
5. 梁小波, 于红宾, 王立平. 胃肠道间质瘤的临床流行病学调查. 肿瘤研究与临床, 2006, 18(8): 505-507.
6. 陈悦, 陈超美, 刘则渊, 等. CiteSpace 知识图谱的方法论功能. 科学学研究, 2015, 33(2): 242-253.
7. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 2010, 84(2): 523-538.
8. 李佼, 周银斌, 周小林, 等. 基于 2013 年至 2017 年 Cite Space 的胃癌手术文献的可视化研究. 局解手术学杂志, 2019, 28(3): 177-182.
9. 黄子星, 李谋, 于浩鹏, 等. 基于 CiteSpace 的胰腺神经内分泌肿瘤影像研究的科学知识图谱分析. 中国普外基础与临床杂志, 2019, 26(1): 96-101.
10. Wu CE, Tzen CY, Wang SY, <italic>et al</italic>. Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view. Cancers (Basel), 2019, 11(5): 679.
11. Demetri GD, von Mehren M, Blanke CD, <italic>et al</italic>. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
12. Dematteo RP, Ballman KV, Antonescu CR, <italic>et al</italic>. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 373(9669): 1097-1104.
13. Demetri GD, van Oosterom AT, Garrett CR, <italic>et al</italic>. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544): 1329-1338.
14. Demetri GD, Reichardt P, Kang YK, <italic>et al</italic>. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 295-302.
15. Guo Y, Jing X, Zhang J, <italic>et al</italic>. Endoscopic removal of gastrointestinal stromal tumors in the stomach: a single-center experience. Gastroenterol Res Pract, 2019, 2019: 3087298.
16. De Vogelaere K, Hoorens A, Haentjens P, <italic>et al</italic>. Laparoscopic <italic>versus</italic> open resection of gastrointestinal stromal tumors of the stomach. Surg Endosc, 2013, 27(5): 1546-1554.
17. Matsuhashi N, Osada S, Yamaguchi K, <italic>et al</italic>. Long-term outcomes of treatment of gastric gastrointestinal stromal tumor by laparoscopic surgery: review of the literature and our experience. Hepatogastroenterology, 2013, 60(128): 2011-2015.
18. Mei L, Du W, Idowu M, <italic>et al</italic>. Advances and challenges on management of gastrointestinal stromal tumors. Front Oncol, 2018, 8: 135.
19. Rutkowski P, Jagielska B, Andrzejuk J, <italic>et al</italic>. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). Contemp Oncol (Pozn), 2017, 21(4): 285-289.
20. 夏训明. 美国 FDA 批准 Ayvakit (avapritinib)用于治疗 PDGFRA 基因 18 外显子突变型胃肠道间质瘤. 广东药科大学学报, 2020, 36(1): 27.
21. Mazzocca A, Napolitano A, Silletta M, <italic>et al</italic>. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol, 2019, 11: 1758835919841946.
22. Tan Y, Trent JC, Wilky BA, <italic>et al</italic>. Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Ther, 2017, 24(3): 130-133.
23. Chen LL, Chen X, Choi H, <italic>et al</italic>. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother, 2012, 61(7): 1113-1124.
24. Balachandran VP, Cavnar MJ, Zeng S, <italic>et al</italic>. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med, 2011, 17(9): 1094-1100.
25. Edris B, Willingham S, Weiskopf K, <italic>et al</italic>. Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncoimmunology, 2013, 2(6): e24452.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Mapping knowledge domains analysis of gastrointestinal stromal tumor research

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content